A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.
Tungsiripat
Marisa
M
Cleveland Clinic and Case Western Reserve University,Cleveland, Ohio 44195, USA. tungsim@ccf.org
Kitch
Douglas
D
Glesby
Marshall J
MJ
Gupta
Samir K
SK
Mellors
John W
JW
Moran
Laura
L
Jones
Lynne
L
Alston-Smith
Beverly
B
Rooney
James F
JF
Aberg
Judith A
JA
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D010865:Pilot Projects; D000068698:Tenofovir; D055815:Young Adult
D019380:Anti-HIV Agents; D063065:Organophosphonates; D002784:Cholesterol; D000068698:Tenofovir; D000225:Adenine